Skip to main content
TARS logo

TARS · Tarsus Pharmaceuticals, Inc.

Track TARS — free
$78.20 -0.48 (-0.61%) At close · Nov 17
Market Cap
$3.86B
Shares
49.31M
Volume · Nov 17 542.25K Avg daily vol (3M) 874.8K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$78.20 Open$78.72 Day$76.18–78.72 52W close$56.11–90.78 Avg vol 30d972K Short int6.1M · 12.3% of shares · 6.9d Short vol60% Last earningsNov 3, 2026 DataOct 2020–Nov 2026 Filing10-Q · Nov 3

Up next

Feb 22, 2027 Est · unconfirmed · in 14 wks

Latest documents

2026
Nov 3
Earnings call
Quarterly sales hit $194.6 million as 2026 outlook rises

Tarsus reported Q3 XTENVI net product sales of $194.6 million and raised full-year 2026 sales guidance to $715 million to $730 million. DTC spending will increase to approximately $95 million.

5 source passages
Xtempi's continued growth is giving us greater opportunities to invest in Tarsus' future. One, increasing demand as more patients recognize their symptoms and ask about XTENVI. Starting with our third quarter results, we delivered Xtembe net product sales of $194.6 million, driven by strong prescription volumes, gross margin of approximately 93%, and we ended the quarter with cash and cash equivalents of approximately $310 million. Now, turning to our updated full-year 2026 guidance, we expect our full-year 2026 Extenvy sales outlook to be between $715 million to $730 million. That's why we're adding $5 million to our DTC spend, bringing our full-year investment to approximately $95 million Open the document at this passage
Nov 3
Quarterly report 10-Q FY2026 Q3, ended Sep 30
XDEMVY sales rise 64% as net loss reaches $668.3 million

Tarsus Pharmaceuticals reported third-quarter 2026 XDEMVY net product sales of $194.6 million, up approximately 64%, but a $668.3 million net loss including $632.2 million of acquired in-process research and development expense.

Revenue $194.57M ▲ 63.9% Net loss $668.33M Diluted EPS -$14.40
Read from the MD&A section
3 source passages
Generated $194.6 million of net product sales of XDEMVY in the U.S. in the third quarter of 2026, a year-over-year increase of approximately 64%. Our net losses were $668.3 million and $12.6 million for the three months ended September 30, 2026 and 2025, respectively Acquired in-process research and development expense (“IPR&D”) was $632.2 million for the three months ended September 30, 2026 Open the document at this passage
Nov 3
Current report 8-K
XDEMVY sales rise 64% to $194.6 million in third quarter

Tarsus reported third-quarter 2026 XDEMVY net product sales of $194.6 million, up approximately 64% year-over-year. Net loss widened to $668.3 million, driven by $632.2 million of acquired in-process R&D from the iRenix and Alkeus acquisitions. Cash, cash equivalents and marketable securities were $309.6 million as of September 30, 2026.

Financial results
4 source passages
XDEMVY generated third quarter 2026 net product sales of $194.6 million, a year-over-year increase of approximately 64%. Net loss: was $668.3 million, compared to $12.6 million for the same period in 2025. were $632.2 million for the period, consisting of $81.0 million related to the acquisition of iRenix and $551.2 million related to the acquisition of Alkeus As of September 30, 2026, cash, cash equivalents and marketable securities were $309.6 million. Open the document at this passage
Oct 13
Registration statement S-3ASR
Registration statement

Tarsus Pharmaceuticals, Inc. registered up to 2,908,692 shares of common stock for resale by selling stockholders; it will receive no proceeds from their sales.

Read from the first part of this long document
Oct 13
Registration statement S-3ASR
Registration statement

Tarsus Pharmaceuticals, Inc. registered up to 2,232,144 shares of common stock for resale by selling stockholders, comprising 2,098,519 shares and 133,625 shares issuable upon exercise of pre-funded warrants. The company will receive no proceeds from share sales.

Read from the first part of this long document
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$682.20M
Trailing 12 months
Net income (TTM)
−$702.23M
Trailing 12 months
Revenue growth YoY
+63.9%
Year over year
Operating margin
-102.0%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
0.8%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$236.68M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+9.0%
Year over year · more shares
Price change (1Y)
+5.4%
Trailing year
Short interest
12.3%
Latest settlement · 6.9 days to cover
View all 125 metrics

AI Brief

Q3 FY26 earnings call · Nov 3, 2026
Q3 FY26

TL;DR. XDEMVY delivered record sales of $194.6 million, up approximately 64% year over year, with approximately 93% gross margin, and management raised 2026 sales guidance to $715 million–$730 million amid broad commercial momentum. Tarsus advanced its pipeline and completed two acquisitions, but reported a $668.3 million net loss, increased R&D and SG&A expenses, material development costs, and deferred TP-03 filings in Europe and Japan.

Bullish
  • + Management raised full-year 2026 XDEMVY sales guidance to $715 million to $730 million.
  • + Commercial momentum was supported by broader ECP prescribing, stronger patient acquisition, and increasing retreatment.
  • + XDEMVY has surpassed one million bottles dispensed and $1 billion in cumulative net product sales since launch.
  • + The pipeline advanced multiple clinical milestones across TP-04, TP-05, IRX-101, and gildeuretinol.
Bearish
  • − Tarsus reported a Q3 net loss of $668.3 million, compared with $12.6 million in the prior-year period.
  • − Management guides to full-year SG&A expense of $605 million to $620 million, with DTC investment increasing by $5 million to approximately $95 million.
  • − Tarsus deferred TP-03 regulatory filings in Europe and Japan because of most favored nation regulations.

AI-generated from the earnings call and 8-K · may contain errors · not investment advice

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 25.5 · fear Equity put/call 0.71
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +15%
above
Price vs 50-day avg +5%
above
RSI (14) 60
neutral
MACD trend Positive
52-week position 64%
mid-range
Momentum
relative strength
Strong
1-month return +10%
trailing
6-month return +31%
trailing
YTD return −4%
this year
Relative strength +34%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $74 › 200d $68 — 50d above 200d
Institutional flow Flat
0% holders QoQ · +44 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
12.30% of shares out · ▲ +5.8% MoM · 6.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
258 holders — near 3-yr high, broad support
Squeeze score 85
high risk · 0–100
Fundamentals
Strong
Revenue growth +147%
Y/Y
EPS growth +48%
Y/Y
Free cash flow $-22.3M
Balance sheet $111.2M
net cash
Quant / Vol
risk profile
Very High
Volatility 45%
annualized · 1-yr
Max drawdown −32%
past year
ATR 4.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Aug 6, 2026
full-year 2026
XTENVI full-year product sales $685M – $705M
Full-year R&D expense Maintained $190M – $210M
Jun 30, 2026 $190M – $210M changed to Aug 6, 2026 $190M – $210M
2026
SG&A expenses Maintained $545M – $565M
Jun 30, 2026 $545M – $565M changed to Aug 6, 2026 $545M – $565M
Previous outlook earlier release · from the Earnings Call filed May 6, 2026

Still-open targets the latest release did not restate under the same label.

R&D expenses · full year 2026 $115M – $135M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
0 · 3 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+15% Bullish
Price vs 50-day avg
+5% Bullish
RSI (14)
60 Neutral
MACD trend
Positive Bullish
52-week position
64% Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50d $74 › 200d $68 — 50d above 200d
Institutional flow Flat
0% holders QoQ · +44 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
12.30% of shares out · ▲ +5.8% MoM · 6.9 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
258 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $56 Now $78 · 64% Range high $91
vs 200-day avg +15% vs 50-day avg +5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
TARS
Tarsus Pharmaceuticals, Inc.
this stock
$3.86B -4.5% +146.7% — 12.3%
VRTX
Vertex Pharmaceuticals Inc
$135.44B +17.8% +46.2% 34.4 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$99.08B +24.1% +20.8% 21.2 2.1%
MRNA
Moderna, Inc.
$83.68B +601.3% +4.3% — 8.2%
CSLLY
Csl Ltd
$64.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
258
% held
106.0%
Net QoQ
+4.9M sh
Top holder
BlackRock, Inc.
Held Float
View
Held by Funds
Fund positions
245
View
Short & Settlement
Short Interest Rising
Shares short
6.1M
Days to cover
6.9d
Change
+335.1K sh
View
Short Volume
Short vol %
60%
As of
Nov 17, 2026
Short Total
View
Fails to Deliver
FTD shares
17.6K
Value
$1.3M
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
51.9%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$451.4M
Net income (FY)
$-66.4M
EPS diluted
$-1.59
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 3, 2026
This year
30

Tarsus Pharmaceuticals reported third-quarter 2026 XDEMVY net product sales of $194.6 million, up approximately 64%, but a $668.3 million net loss including $632.2 million of acquired in-process research and development expense.

View
Proposed Sales
Value
$387.9K
Shares
4.6K
Filed
Sep 4, 2026
View
Earnings & Events
Webcasts
Last webcast
Nov 10, 2026
View
Investor Relations
Latest news
Tarsus Reports Third Quarter 2026…
Published
Nov 3, 2026
View

Performance

5D 20D 120D MTD YTD
TARS +5.9% +10.1% +31.3% +4.5% -4.5%
SPY -2.3% -4.8% -2.9% -3.1% +7.4%
vs SPY +8.3% +14.9% +34.3% +7.6% -11.9%
Key facts CIK 1819790 CUSIP 87650L103 13F (30d) 263 filings 247 filers Visit website Investor relations